Biomarkers downregulated in prostate cancer

Details Biomarkers downregulated in prostate cancer Biomarkers downregulated in prostate cancer

2011-08-30

2011-08-30

Aeder, Sean (Department: 1642)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

Reexamination Certificate

active

08008012

ABSTRACT:
Biomarkers are identified by analyzing gene expression data using support vector machines (SVM), recursive feature elimination (RFE) and/or linear ridge regression classifiers to rank genes according to their ability to separate prostate cancer from normal tissue. Proteins expressed by identified genes are detected in patient samples to screen, predict and monitor prostate cancer.

REFERENCES:
patent: 5143854 (1992-09-01), Pirrung et al.
patent: 5552277 (1996-09-01), Nelson et al.
patent: 5837832 (1998-11-01), Chee et al.
patent: 5972615 (1999-10-01), An et al.
patent: 6107103 (2000-08-01), Xuan et al.
patent: 6128608 (2000-10-01), Barnhill
patent: 6171796 (2001-01-01), An et al.
patent: 6395479 (2002-05-01), Reichardt et al.
patent: 6427141 (2002-07-01), Barnhill
patent: 6511806 (2003-01-01), Freuhauf et al.
patent: 6566130 (2003-05-01), Srivastava et al.
patent: 6685395 (2004-02-01), Busby
patent: 6692916 (2004-02-01), Bevilacqua et al.
patent: 6714925 (2004-03-01), Barnhill et al.
patent: 6760715 (2004-07-01), Barnhill et al.
patent: 6789069 (2004-09-01), Barnhill et al.
patent: 6882990 (2005-04-01), Barnhill et al.
patent: 6949342 (2005-09-01), Golub et al.
patent: 6960439 (2005-11-01), Bevilacqua et al.
patent: 7252935 (2007-08-01), Sidransky
patent: 2001/0007748 (2001-07-01), An et al.
patent: 2002/0151681 (2002-10-01), Rosen
patent: 2002/0168638 (2002-11-01), Schlegel et al.
patent: 2003/0049645 (2003-03-01), Mu et al.
patent: 2003/0087818 (2003-05-01), Jiang
patent: 2003/0108963 (2003-06-01), Schlegel
patent: 2003/0113762 (2003-06-01), Warrington
patent: 2003/0138793 (2003-07-01), Su et al.
patent: 2003/0172043 (2003-09-01), Guyon et al.
patent: 2003/0175736 (2003-09-01), Chinnaiyan et al.
patent: 2003/0180738 (2003-09-01), Rees et al.
patent: 2003/0215835 (2003-11-01), Sun et al.
patent: 2004/0009481 (2004-01-01), Schlegel et al.
patent: 2004/0029151 (2004-02-01), Mahadevappa et al.
patent: 2004/0092469 (2004-05-01), Srivastava et al.
patent: 2004/0110221 (2004-06-01), Twine et al.
patent: 2004/0121413 (2004-06-01), Aebersold et al.
patent: 2004/0133352 (2004-07-01), Bevilacqua et al.
patent: 2004/0137455 (2004-07-01), Dong et al.
patent: 2004/0175743 (2004-09-01), Burczinski et al.
patent: 2004/0203012 (2004-10-01), Diamandis
patent: 2004/0225449 (2004-11-01), Bevilacqua et al.
patent: 2004/0235071 (2004-11-01), Lightcap et al.
patent: 2004/0259086 (2004-12-01), Schlegel et al.
patent: 2005/0009771 (2005-01-01), Levanon et al.
patent: 2005/0032065 (2005-02-01), Afar et al.
patent: 2005/0112134 (2005-05-01), Graddis et al.
patent: 2005/0112678 (2005-05-01), Yang
patent: 2005/0119210 (2005-06-01), Be et al.
patent: 2005/0136493 (2005-06-01), Rubin et al.
patent: 2005/0191673 (2005-09-01), Schlegel et al.
patent: 2005/0227917 (2005-10-01), Williams
patent: 2005/0244843 (2005-11-01), Chen et al.
patent: 2005/0244973 (2005-11-01), Andel et al.
patent: 2005/0259483 (2005-11-01), Nakamura et al.
patent: 2005/0272061 (2005-12-01), Petroziello et al.
patent: 2006/0019256 (2006-01-01), Clarke et al.
patent: 2006/0134688 (2006-06-01), Welsh
patent: 2006/0211017 (2006-09-01), Chinnaiyan et al.
patent: 2006/0269546 (2006-11-01), Srivastava et al.
patent: 2007/0014801 (2007-01-01), Gish
patent: 2007/0041944 (2007-02-01), Iavarone
patent: 2007/0048738 (2007-03-01), Donkena et al.
patent: 2007/0059712 (2007-03-01), Gish
patent: 2007/0065856 (2007-03-01), Belacel et al.
patent: 2007/0099209 (2007-05-01), Clarke et al.
patent: 2007/0105133 (2007-05-01), Clarke et al.
patent: 2007/0212702 (2007-09-01), Tomlins et al.
patent: 2008/0254455 (2008-10-01), Wang et al.
patent: 0055174 (2000-09-01), None
patent: 02053223 (2002-07-01), None
patent: 2004090163 (2004-10-01), None
patent: 2005015236 (2005-02-01), None
Tockman et al (Cancer Res., 1992, 52:2711s-2718s).
Alberts et al. (Molecular Biology of the Cell, 3rd edition, 1994, p. 465).
Greenbaum et al. (Genome Biology, 2003, vol. 4, Issue 9, pp. 117.1-117.8).
Goessl et al (Cancer Research, 2000, 60(21):5941-5945).
Aerts, H., “Chitotriosidase—New Biochemical Marker”,Gauchers News, Mar. 1996.
Albrecht, et al., “Expression, localization and activity of neutral endopeptidase in cultured cells of benign prostatic hyperplasia and prostate cancer”,J Urol., Jul. 2002, pp. 336-342, vol. 168(1) (Abstract).
Alizadeh, et al., “Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling”,Nature, Feb. 3, 2000, vol. 403(6769) (Abstract).
Alon, et al., “Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon cancer tissues probed by oligonucleotide arrays”,PNAS, Cell Biology, Jun. 1999, pp. 6745-6750, vol. 96.
Bauer, et al., “Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer”,J Urol., Oct. 1996, pp. 1511-1516, vol. 156(4) (Abstract).
Beer, et al., “Polymorphisms of GSTP1 and related genes and prostate cancer risk”,Prostate Cancer Prostatic Dis., 2002, pp. 22-27, vol. 5(1) (Abstract).
Borre, et al., “p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting”,J Urol., Sep. 2000, pp. 716-721, vol. 164(3 Pt 1) (Abstract).
Burns-Cox, et al., “Changes in collagen metabolism in prostate cancer: a host response that may alter progression”,J Urol., Nov. 2001, pp. 1698-1701, vol. 166(5) (Abstract).
Caine, et al., “Plasma angiopoietin-1, angiopoietin-2 and Tie-2 in breast and prostate cancer: a comparison with VEGF and Flt-1”,Eur J Clin Invest., Oct. 2003, pp. 883-890, vol. 33(10) (Abstract).
Depinieux, et al., “Clinical and experimental progression of a new model of human prostate cancer and therapeutic approach”,Am J Pathol., Aug. 2001, pp. 753-764, vol. 159(2).
Deprimo, et al., “Transcriptional Programs Activated by Exposure of Human Prostate Cancer Cells to Androgen”,Genome Biology, 2002, vol. 3(7).
Dhanasekaran, et al., “Delineation of prognostic biomarkers in prostate cancer”,Nature, Aug. 23, 2001, pp. 822-826, vol. 412(6849) (Abstract).
Ernst, et al., “Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue”,Am J Pathol., Jun. 2002, pp. 2169-2180, vol. 160(6).
Febbo et al., “Use of expression analysis to predict outcome after radical prostatectomy”,The journal of urology, Dec. 2003, pp. 811-820, vol. 170.
Floryk, et al., “Differentiation of Human Prostate Cancer PC-3 Cells Induced by Inhibitors of Inosine 5′-Monophosphate Dehydrogenase”,Cancer Research, Dec. 15, 2004, pp. 9049-9056, vol. 64.
Fujarewicz, et al., “Selecting differentially expressed genes for colon tumor classification”,Int. J. Appl. Math. Comput. Sci., 2003, pp. 327-335, vol. 13, No. 3.
Gelmann, et al., “Expression of genes and proteins specific for prostate cancer”,J Urol., Nov. 2004, pp. S23-6;, vol. 172(5 Pt 2), discussion S26-7, (Abstract).
Ghigna, et al., “Altered Expression of Heterogeneous Nuclear Ribonucleoproteins and SR Factors in Human”,Cancer Research, pp. 9212-9217, vol. 58, 5818-5824 (Abstract).
Glinsky, et al., “Gene expression profiling predicts clinical outcome of prostate cancer”,J Clin Invest., Mar. 2004. pp. 806-808, vol. 113(6).
Golub, et al., “Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring”,Science, Oct. 15, 1999, pp. 531-537, vol. 286.
Guyon, et al., “Gene Selection for Cancer Classification using Support Vector Machines”,Machine Learning, 2002, pp. 389-422, vol. 46.
Harden, et al., “Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma”,J Urol., 2003, pp. 1138-1142, vol. 169(3)

Affiliated with

Also associated with

Rating

Biomarkers downregulated in prostate cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Biomarkers downregulated in prostate cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biomarkers downregulated in prostate cancer will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2734358